Background: Different clinical studies have given inconsistent results on whether the use
of antipsychotics increases the risk of thromboembolism. In this paper, we reviewed all relevant literature
to provide suggestions for clinical diagnosis and treatment.
Methods: PubMed, Web of Science, EMBASE, MEDLINE, Cochrane and Scopus databases were
thoroughly searched up to June 2019. Two researchers independently searched the literature, extracted
data. Data were analyzed by Stata 12.0 software.
Results: A total of 22 studies involving 31514226 subjects were included. This meta-analysis showed
that patients taking the first- or second-generation antipsychotics had a higher risk of venous thromboembolism
and pulmonary embolism than those who did not, and low potency first-generation agents
increased the risk of venous thromboembolism more than high potency antipsychotics, and olanzapine,
clozapine, haloperidol, perphenazine and risperidone also significantly increased the risk of it.
The risk of venous thrombosis in obese people was higher than that in overweight people, patients not
less than 65 years old had an increased risk compared with younger patients. In addition, women taking
antipsychotics had a higher risk of pulmonary embolism than men.
Conclusion: The use of antipsychotics will increase the risk of venous thromboembolism and pulmonary
embolism, which will be affected by the type of antipsychotics and patient characteristics.